Smith K L, Butler W R, Overton T R
Department of Animal Science, Cornell University, Ithaca, NY 14853, USA.
J Dairy Sci. 2009 Aug;92(8):3623-33. doi: 10.3168/jds.2008-1508.
Thiazolidinediones (TZD) are potent synthetic ligands for peroxisome proliferator-activated receptor-gamma that have been shown previously to reduce plasma nonesterified fatty acids and increase peripartal dry matter intake (DMI) in dairy cows. Data from Holstein cows (n = 36) entering their second or greater lactation were used to determine whether late prepartum administration of TZD would affect periparturient metabolism, milk production, and ovarian activity. Cows were administered 0, 2.0, or 4.0 mg of TZD/kg of BW by intrajugular infusion once daily from 21 d before expected parturition until parturition. Plasma samples were collected daily from 22 d before expected parturition through 21 d postpartum and twice weekly from wk 4 through 9 postpartum. In response to increasing TZD dosage, plasma nonesterified fatty acid concentrations decreased linearly during the postpartum period (d 0 to +21: 348, 331, 268 +/- 31 microEq/L, respectively). Plasma concentrations of glucose were highest in cows administered 4.0 mg of TZD/kg of BW during the peripartum and postpartum periods (d -7 to +7: 57.9, 57.8, 61.1 +/- 0.8 mg/dL and d 0 to +21: 51.6, 49.3, 54.7 +/- 1.1 mg/dL, respectively). Plasma concentrations of beta-hydroxybutyrate were increased during the peripartum period by TZD administration (9.6, 9.9, 10.2 +/- 0.3 mg/dL) but were not affected during the postpartum period. Plasma insulin was not affected by treatment during any time period. Postpartum liver triglyceride content was decreased linearly (11.0, 10.4, 4.2 +/- 1.6%) and glycogen content was increased linearly (2.16, 2.38, 2.79 +/- 0.19%) by prepartum TZD administration. Prepartum TZD administration linearly increased DMI during the peripartum period (d -7 to +7: 16.1, 17.2, 17.3 +/- 0.5 kg/d). Cows administered TZD prepartum maintained higher postpartum body condition scores than control cows (wk 1 through 9: 2.77, 2.89, 3.02 +/- 0.05). There was no effect of prepartum TZD on milk yield; however, yields of 3.5% fat-corrected milk (52.2, 54.6, 48.0 +/- 1.6 kg/d) and most other milk components were decreased in cows that received 4.0 mg of TZD/kg of BW prepartum. Prepartum TZD administration linearly decreased the number of days to first ovulation (29.3, 28.3, 19.0 +/- 3.6 d). These results suggest that prepartum administration of TZD improves metabolic health and DMI of periparturient dairy cows and may decrease reliance on body fat reserves during early lactation.
噻唑烷二酮类(TZD)是过氧化物酶体增殖物激活受体γ的强效合成配体,此前已证明其可降低奶牛血浆中非酯化脂肪酸水平,并增加围产期干物质摄入量(DMI)。本研究使用进入第二胎或更高胎次泌乳期的荷斯坦奶牛(n = 36)的数据,来确定产前晚期给予TZD是否会影响围产期代谢、产奶量和卵巢活动。从预计分娩前21天至分娩,奶牛每天通过颈静脉输注给予0、2.0或4.0 mg TZD/kg体重。从预计分娩前22天至产后21天每天采集血浆样本,产后第4周通过第9周每周采集两次。随着TZD剂量增加,产后期间血浆非酯化脂肪酸浓度呈线性下降(产后0至 +21天:分别为348、331、268±31微当量/升)。围产期和产后期间给予4.0 mg TZD/kg体重的奶牛血浆葡萄糖浓度最高(产前 -7至产后 +7天:分别为57.9、57.8、61.1±0.8毫克/分升;产后0至 +21天:分别为51.6、49.3、54.7±1.1毫克/分升)。围产期给予TZD可使血浆β-羟基丁酸酯浓度升高(9.6、9.9、10.2±0.3毫克/分升),但产后期间不受影响。任何时间段治疗均不影响血浆胰岛素水平。产前给予TZD可使产后肝脏甘油三酯含量呈线性下降(11.0、10.4、4.2±1.6%),糖原含量呈线性增加(2.16、2.38、2.79±0.19%)。产前给予TZD可使围产期DMI呈线性增加(产前 -7至产后 +7天:16.1、17.2、17.3±0.5千克/天)。产前给予TZD的奶牛产后体况评分高于对照组奶牛(第1周通过第9周:2.77、2.89、3.02±0.05)。产前TZD对产奶量无影响;然而,产前给予4.0 mg TZD/kg体重的奶牛,其3.5%脂肪校正乳产量(52.2、54.6、48.0±1.6千克/天)和大多数其他乳成分均下降。产前给予TZD可使首次排卵天数呈线性减少(29.3、28.3、19.0±3.6天)。这些结果表明,产前给予TZD可改善围产期奶牛的代谢健康和DMI,并可能减少早期泌乳期间对体脂储备的依赖。